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aBstraCt
Racemose haemangiomatosis of the retina is a sporadic, mostly unilateral, congenital arteriovenous malformation 
(AVM), comprising abnormal junctions between arteries and veins that omit capillaries. Typically, vascular malfor-
mations are asymptomatic and incidentally discovered. Advanced changes may be related to the presence of subreti-
nal fluid and exudates, even though these lesions are classified as benign. Many complications can lead to severe or 
permanent visual impairment. Direct methods of treatment of primary retinal vascular anomalies have not been 
developed yet. The aim of this case report is to present the anti-VEGF therapy in the treatment macular oedema 
secondary to racemose haemangioma.
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introduCtion
The vascular tumours of the retina comprise 
a diverse group of congenital and acquired lesions, 
that include capillary haemangioma, cavernous hae-
mangioma, racemose haemangiomatosis, and reti-
nal vasoproliferative tumour [1, 2].
Racemose haemangiomatosis of the retina is 
a  sporadic, mostly unilateral, congenital arterio-
venous malformation (AVM), comprising abnor-
mal junctions between arteries and veins that omit 
capillaries. If similar vascular malformations coexist 
in the same side of the brain, that relation is con-
sidered as a Wyburn-Mason syndrome (also known 
as Bonnet-Dechaumme-Blanc syndrome). Lesions 
may also be located in the skin, bones, muscles, 
kidneys, and in gastrointestinal tract [3, 4]. Typical 
clinical manifestation reveals characteristic dilated 
and tortuous retinal vessels that can extend from 
the optic disc to the retinal periphery [5]. Depend-
ing upon the severity of the vascular malformation, 
they are classified into three distinct groups: Group 
I AVMs possesses abnormal capillary plexus between 
the large vessels; Group II shows a lack of capillary 
vessels; and Group III includes the most extensive 
AVMs, with dilated and tortuous vessels [6].
Fluorescein angiography (FA) demonstrates anom-
alous arteriovenous communications and the hyper-
fluorescense without leakage (Fig. 1). Typically, vascu-
lar malformations are asymptomatic and incidentally 
discovered. Bigger changes may be related with the 
presence of subretinal fluid and exudates. In the diag-
nosis and monitoring of the disease, optical coherence 
tomography (OCT) is found to be useful [7].
Anti-VEGF therapy is an option in managing 
complications of retinal arteriovenous anomalies [8].
Case report
A  41-year-old female patient reported to the 
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University in Lublin complaining about deteriora-
tion of vision in her right eye. In a clinical examina-
tion, we found that the best corrected visual acuity 
(BCVA) in the right eye was 0.3, and in the left eye 
— 1.0. Examination of the anterior segment of the 
both eyes with a  slit lamp showed no abnormali-
ties. Fundus examination of the right eye revealed 
the presence retinal racemose haemangioma (Fig. 2) 
and secondary macular oedema. OCT of the right 
eye showed cystoid macular oedema (CMO) (Fig. 3).
The patient was qualified to intravitreal injection 
of anti-VEGF (Vascular Endothelial Growth Fac-
tor) — bevacizumab to her right eye. One month 
Figure 1. Fluorescein angiogram (FA) of the right eye. a. FA image showing arteriovenous malformations. B. FA image confirm the char-
acteristic absence of leakage from the AVMs
Figure 2. Colour photography of the right eye fundus — race-
mose haemangiomatosis of retina
Figure 3. Optical coherence tomography image of the right eye 
— macular oedema
after intravitreal injection of bevacizumab, BCVA 
in the right eye improved, reaching 0.8. Fundus 
examination and OCT of the right eye revealed no 
macular oedema. After two months of observation 
the patient achieved full visual acuity. OCT exam-
ination showed complete absorption of subretinal 
fluid (Fig. 4).
disCussion
Retinal vascular malformations are benign, 
usually asymptomatic, and discovered incidentally 
during ophthalmologic examination. However, in 
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many cases, they can cause significant deterioration 
of vision by various mechanisms. Blood vessels tor-
tuosity can lead to the closure of their barrel [9, 10], 
retinal ischaemia [11], and neovascular glaucoma [12]. 
It can also lead to macular haemorrhage, serous pig-
ment epithelium detachment, and cystoid macular 
oedema [13, 14].
Direct methods of treatment of primary retinal 
vascular anomalies have not been developed yet. 
Only the above-mentioned complications are cov-
ered by the treatment. In 2006 Soliman et al. de-
scribed a case of treatment of a patient with bilateral 
racemose haemangioma by photocoagulation of the 
vascular leakage points [15]. However, considering 
the age of patients, the incidence of CMO near the 
fovea, and the risk of subretinal choroidal neovascu-
larization, which entails photocoagulation, treatment 
with anti-VEGF preparations is much safer [16].
Currently, the literature describes one case of 
treatment CMO in the course of retinal racemose 
haemangioma by intravitreal injection of bevaci-
zumab [16]. The exact mechanism of action in this 
case is unknown; however, by decreasing the vascu-
lar permeability and increasing the number of tight 
junctions between proteins a  significant reduction 
of subretinal fluid was obtained [16].
In our case intravitreal injection of bevacizumab 
resulted in complete regression of the CMO in the 
right eye, which was associated with the return of 
full visual acuity. The therapy applied in this case was 
a safe and effective method against cystoid macular 
oedema in the course of retinal racemose haeman-
gioma. At the time of writing, after six months of 
observation, the macular oedema has not recurred. 
However, patients with racemose haemangiomatosis 
of the retina should be carefully monitored because 
such treatment is directed towards secondary retinal 
changes, not to the primary disease.
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Figure 4. Optical coherence tomography image of the right eye, 
showing complete elimination of subretinal fluid after anti­VEGF injection
